MedTrace Logo

Pretreatment With Dienogest in Women With Endometriosis Undergoing in Vitro-fertilization After a Previous Failed Cycle

NCT04306276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2020-03-12

No results posted yet for this study

Summary

It is generally assumed that the major causes of in vitro fertilization (IVF) failure in women with endometriosis are diminished ovarian reserve, impaired endometrial receptivity and low quality of embryos. The use of prolonged courses of hormone therapy may play an important role in the strategy of overcoming endometriosis-related infertility. The aim of this study was to evaluate the use of dienogest (DNG) before an IVF cycle in women with endometriosis undergone a previous IVF failed cycle

Conditions

  • Endometriosis
  • Endometriosis Ovary
  • IVF

Interventions

DRUG

Dienogest 2 MG

Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF

Sponsors & Collaborators

  • Ospedale Policlinico San Martino

    lead OTHER

Principal Investigators

  • Fabio Barra, MD, PhD · IRCCS Ospedale Policlinico San Martino

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-03-01
Completion
2020-03-01
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306276 on ClinicalTrials.gov